Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Centre Hospitalier Universitaire Vaudois
NRG Oncology
Mayo Clinic
Eastern Cooperative Oncology Group
University of Massachusetts, Boston
Centre Oscar Lambret
Centre Oscar Lambret
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Case Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
University of California, San Diego
Emory University
Ohio State University Comprehensive Cancer Center
National Medical Research Radiological Centre of the Ministry of Health of Russia
University of California, San Diego
Aveta Biomics, Inc.
M.D. Anderson Cancer Center
Sir Mortimer B. Davis - Jewish General Hospital
M.D. Anderson Cancer Center
University of California, San Diego
University of Michigan Rogel Cancer Center
UNC Lineberger Comprehensive Cancer Center
Oslo University Hospital
Jiangsu Cancer Institute & Hospital
Erasmus Medical Center
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
University of Utah
EpicentRx, Inc.
EpicentRx, Inc.
University of Arizona
Eastern Cooperative Oncology Group
University of California, San Francisco
Sun Yat-sen University
Shanghai Jiao Tong University School of Medicine
Shanghai Jiao Tong University School of Medicine
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Shanghai Jiao Tong University School of Medicine
Celldex Therapeutics